A team at St. Jude Children's Research Hospital has created a tool to visualize the mutations that lead to pediatric cancers. The free application, called ProteinPaint, displays genetic lesions such as sequence mutations and gene fusion alongside RNA expression.
Cancer Research UK has unveiled version 3.0 of its oncology drug discovery database. The latest iteration of the platform contains more than 110,000 3-D structures for nearly 22,000 proteins, a resource the team behind the database thinks will support improved target selection.
As World Health Organization figures show China rising to the top of the list of countries with the most cancer cases, its people are facing increasing problems in trying to find ways to pay for their treatments. Healthcare costs are soaring in the nation despite the government's efforts to force drug prices lower.
China's Kelun Pharmaceutical has just opened a $50 million production plant in Almaty (formerly Alma-Ata), just across the border in Kazakhstan. Kelun Kazpharm executives told China's state-run Xinhua news agency the plant is responsible for 70% of the Kazakhstan market for intravenous medicines.
An affiliate of Hong Kong-listed Lee's Pharmaceutical Holdings has licensed the TG02 oncology treatment developed by California-based Tragara Pharmaceuticals, the companies said in a statement.
Cardiovascular-focused Boston Scientific is moving deeper into oncology and expanding its vascular offerings with the purchase of the interventional radiology portfolio of CeloNova BioSciences. The deal with the San Antonio, TX-based startup involves a $70 million upfront payment with additional, undisclosed regulatory and sales milestones.
Another startup is emphatically advancing into the fray to elicit and apply genomic data as a guide for cancer diagnoses and treatment. Personal Genome Diagnostics has raised a $21.4 million Series A round to expand its commercial genomic oncology testing service.
China's Innovent Biologics has deepened a pact with Eli Lilly by including immuno-oncology bispecific antibodies for Innovent in Greater China and for the Indianapolis-based firm outside of the country, setting a new benchmark in a white-hot area of collaboration deals.
Onkos Surgical has secured a Series A financing and partnered with MicroPort Orthopedics. The financial details were undisclosed in the company's announcement, but an SEC filing reveals that Onkos recently secured the first $6.1 million of a financing that's expected to total $15.3 million.
Japan's Eisai said it will present a series of clinical results on Lenvima (lenvatinib) and Halaven (eribulin), among other papers, at the European Cancer Congress, as the company works to grow its key oncology business.